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ABSTRACT
RNA-binding protein Musashi-2 (MSI2) is a key regulator in stem cells, it is 
over-expressed in a variety of cancers and its higher expression is associated with 
poor prognosis. Like Musashi-1, it contains two N-terminal RRMs (RNA-recognition 
Motifs, also called RBDs (RNA-binding Domains)), RRM1 and RRM2, which mediate the 
binding to their target mRNAs. Previous studies have obtained the three-dimensional 
structures of the RBDs of Musashi-1 and the RBD1:RNA complex. Here we show the 
binding of MSI2-RRM1 to a 15nt Numb RNA in Fluorescence Polarization assay and 
time resolved Fluorescence Resonance Energy Transfer assay. Using nuclear magnetic 
resonance (NMR) spectroscopy we assigned the backbone resonances of MSI2-RRM1, 
and characterized the direct interaction of RRM1 to Numb RNA r(GUAGU). Our NMR 
titration and structure modeling studies showed that MSI2-RRM1 and MSI1-RBD1 
have similar RNA binding events and binding pockets. This work adds significant 
information to MSI2-RRM1 structure and RNA binding pocket, and contributes to the 
development of MSI2 specific and MSI1/MSI2 dual inhibitors.
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 INTRODUCTION
RNA-binding proteins (RBPs) are important 
regulators of mRNA stability and translation, and 
dysregulation of RBPs is implicated in many disease 
conditions including cancer. The RNA-binding protein 
Musashi-2 (MSI2) is one of the Musashi family of 
RNA-binding proteins that plays redundant as well as 
independent roles as Musashi-1 (MSI1) in stem cells 
[1–4]. MSI2 has recently been found to be over-expressed 
in many cancers, including hematologic malignancies 
[5–11], colorectal adenocarcinomas [12–14], lung [15], 
pancreatic cancers [16–18], and glioblastoma [19]. It 
maintains cancer stem cell populations and regulates 
cancer invasion, metastasis and development of more 
aggressive cancer phenotypes, including drug resistance, 
by mediating mRNA stability and translation of proteins 
that involve in oncogenic pathways (summarized in 
[20–22]). Overexpression of MSI2 has led to drug 
resistance in ovarian cancer cells [23], promotes invasion 
and metastasis in colorectal cancer, non-small cell lung 
cancer and pancreatic cancer [14, 15, 17]. Knocking down 
of MSI2 sensitizes cancer cells to treatment in ovarian 
cancer cells and in acute myeloid leukemia [23, 24], 
MSI2 depletion stimulates an epithelial to mesenchymal 
phenotype [15]. These findings suggest that MSI2 is a 
promising therapeutic target for cancer. 
Both Musashi proteins belong to the class A/B 
heterogeneous nuclear ribonucleoproteins (hnRNPs). 
They each have two N-terminal RRMs (RNA-recognition 
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Motifs, also called RBDs (RNA-binding Domains)), 
RRM1 and RRM2, which mediate the binding to their 
target mRNAs [3]. Like MSI1, MSI2 post-transcriptionally 
regulates mRNAs by binding to the recognition motifs 
located at 3ʹ-UTR of target mRNAs. One of the motifs, 
r(UAG), was shared between MSI1 and MSI2 [25, 26]. 
The residues that recognize r(UAG) in MSI1 are highly 
conserved between MSI1 and MSI2 [26]. 
MSI1 and MSI2 share several overlapping targets 
that are involved in oncogenic pathways (summarized 
in [20, 22]). One of the targets is Numb [6, 7, 27, 28], a 
negative regulator of the Notch signaling. MSI proteins 
bind to Numb mRNA and inhibits its translation, leading 
to elevated Notch signaling, increased proliferation 
and survival, and decreased apoptosis of cancer cells. 
Specifically, Ito et al. reported in Nature that the Musashi-
Numb pathway can control the differentiation of Chronic 
myelogenous leukemia (CML); expression of Numb 
as a result of MSI2 loss impairs the development and 
propagation of blast crisis CML in vitro and in vivo [6]. 
The solution structures of the two N-terminal RBDs 
of mouse Msi1 and their interactions with RNA have been 
studied extensively [25, 26, 29, 30]. The two RBDs of 
mouse Msi1 share the same ribonucleoprotien (RNP)-type 
fold, and MSI1-RBD1 can specifically bind to RNA by 
stacking interactions between aromatic residues and RNA 
bases. However, no study to date has examined Msi2/MSI2 
residues that directly interact with RNA, and there are no 
high-resolution Msi2/MSI2 RRMs structures available. 
Thus, investigation of how RRMs of MSI2 interact with 
RNA can contribute to identifying novel compounds that 
can disrupt these unique MSI2-RNA interactions. Currently, 
there are three studies including ours in developing small-
molecule inhibitors of MSI. The inhibitors identified from 
these studies have Ki values ranging from ~0.5 µM to 5 µM 
[31–33], yet the most potent one (–)-gossypol (Ki~0.5 µM) 
from our study is not MSI specific [33]. With the help of 
structure-based rational design based on NMR structure, we 
will develop more potent and specific MSI inhibitors. 
Here we characterize MSI2-RRM1 and RNA 
interactions by FP (florescence polarization), TR-FRET 
(time resolved Fluorescence Resonance Energy Transfer). 
We also describe an NMR (Nuclear Magnetic Resonance 
Spectroscopy) investigation of backbone assignment of 
MSI2-RRM1 and its intermolecular interactions with RNA. 
Based on these studies, we identified the RNA-binding 
pocket of MSI2-RRM1, and revealed the similarities between 
the binding pockets of MSI2-RRM1 and MSI1-RBD1. 
RESULTS
Musashi-2-Numb RNA binding 
Here we show that the NumbFITC but not a Control 
RNA (ControlFITC) with a scrambled sequence binds 
to MSI2-RRM1, as indicated by the increase FP value 
(Figure 1A). Such binding is also evident in TR-FRET 
assay (Figure 1B). Using biotinylated Numb RNA 
(NumbBiotin: 5ʹUAGGUAGUAGUUUUA-Biotin), the 
TR-FRET assay detects a Kd of 2.07 nM, whereas a 
Control RNA (ControlBiotin), a Numb mutant (Numb-
mutBiotin: 5ʹUAGCAUCAUCAUUUA-Biotin) or a non-
labelled Numb (Figure 1B) show no detectable binding in 
the nM range. A competition assay on preformed MSI2-
RRM1-NumbBiotin complex indicates that only Numb but 
not Control RNA can displace NumbBiotin (Figure 1C).
Backbone assignment 
To keep the amino acid numbers of recombinant 
MSI2-RRM1 consistent with those of MSI2, residues 
of the recombinant MSI2-RRM1 are numbered starting 
from negative 3. In other words, the first residue of 
the N-terminal hexahistidine tag is M-3, and K111 is 
the C-terminal end. Residues M-3 to A20 comprise the 
N-terminal hexahistidine tag and TEV protease recognition 
site. G21 is the first residue found in MSI2-RRM1, and it 
corresponds to G21 in MSI2 sequence (Figure 5A). 
Figure 2 shows the 2D 1H-15N HSQC spectrum of 
MSI2-RRM1 annotated with the 1H, 15NH assignment of 
residues G21-K111 and W30 side chain NHε. Overall, 
92.6% of the non-proline backbone resonances were 
assigned. Residues not assigned at this time are M-3 
through S4 in the hexahistidine tag, and S18 in the TEV 
protease recognition site. Backbone 1H, 15N, and 13C 
assignments have been deposited in the BMRB data bank 
under accession number 27111. 
RNA titration
To map the RNA-binding interface of MSI2-RRM1, 
we titrated 5 nt Numb (Numb5: GUAGU) stepwise into 
15N labeled protein, and recorded a series of 2D 1H-15N 
HSQC spectra. Significant perturbations of the chemical 
shifts of many backbone resonances of MSI2-RRM1 are 
evident upon binding (Figure 3A). The chemical shift 
changes reached a plateau at 1:1 molar ratio of MSI2-
RRM1:Numb5, indicating a 1:1 stoichiometry of MSI2-
RRM1 and Numb5 complex. The peaks of many residues 
broadened or disappeared at substoichiometirc ratios of 
MSI2-RRM1:Numb5, and reappeared at new positions 
at 1:1 stoichiometric ratio of MSI2-RRM1:Numb5. 
For some residues, their resonances shifted to nearby 
positions, while for others, the chemical shifts were 
perturbed so significantly that the new locations cannot 
be determined. This behavior may result from direct 
binding of ligand to protein in which the free and bound 
states undergo slow exchange in the NMR chemical shift 
time scale, or ligand induced conformational changes. 
Chemical shift perturbations (CSPs) were calculated to 
identify residues that are involved in interacting with 
Numb5. Since the chemical shifts of seven residues I25, 
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G27, W30, S61, R62, G65 and F97 were perturbed so 
significantly that the new locations cannot be determined, 
we acquired the 15N-edited NOESY-HSQC spectrum of 
MSI2-RRM1:Numb5 complex, and assigned the backbone 
1H and 15NH resonances of the seven residues in the 
bound state. CSPs were plotted against residue number 
(G21-K111) in Figure 3B. Residues exhibiting CSPs 
higher than one standard deviation above the average 
are G21, K22, F24, I25, G26, G27, S29, W30, Q31, T32, 
C50, S61, R62, G63, G65, F66, K94 V95 and F97. These 
nineteen residues interact directly or indirectly with the 
Numb5 RNA oligomer.
MSI2-RRM1 structure prediction
A model of MSI2-RRM1 was generated using 
CS-ROSETTA. This program utilizes protein backbone 
chemical shifts to select protein fragments from the 
protein data bank (PDB), followed by Rosetta Monte 
Carlo assembly and relaxation methods. The CS-
ROSETTA program has been shown to be effective in 
de novo structure prediction for small proteins (≤16 kDa) 
[34, 35]. Residues in the N-terminus (M-3-K22) and 
C-terminus (A101-K111) are highly flexible and thus were 
excluded in the CS-ROSETTA calculation. A total of 25,000 
structures were generated. The 10 lowest energy structures 
were selected and their averaged Cɑ root-mean-square-
deviation (RMSD) against the lowest structure is 0.933 ± 
0.284 Å. The superposition of the backbone atoms of the 
10 lowest energy CS-ROSETTA structures and the ribbon 
diagram representation of the lowest energy structure for 
MSI2-RRM1 are shown in Figure 4A and 4B. The lowest 
energy structure is composed of five β-sheets (β1–β5) at 
residues 24–26, 47–52, 64–69, 84–86 and 89–96, and two 
ɑ helices (ɑ1 and ɑ2) at residues 34–43 and 73–81. 
A homology model of MSI2-RRM1 was also 
constructed (Figure 4C). This model relies on the 
NMR structure of MSI1-RBD1: Numb5 complex [26] 
Figure 1: MSI2-RRM1 binds to Numb RNA. (A) Binding between RNA Recognition Motif 1 (aa 21-111) of MSI2 (MSI2-RRM1) 
to Numb RNA (NumbFITC: 5ʹ-UAGGUAGUAGUUUUA-FITC-3ʹ), but not to ControlFITC in FP assay. The concentration of FITC tagged-
RNA used in the assay is 2 nM. (n > 3) (B) Binding between MSI2-RRM1 to Numb RNA (NumbBiotin), but not to Numb-mutBiotin , ControlBiotin, 
or non-labelled Numb in TR-FRET assay. The concentration of RNA used in the assay is 2 nM. (n > 3) (C) Increasing concentrations of 
unlabeled Numb or Control RNAs were added to the preformed NumbBiotin-MSI2-RRM1 complexes in TR-FRET. Numb can displace 
NumbBiotin. Displacement of NumbBiotin at high concentrations of Control RNA are due to non-specific binding. (n > 3).
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as a template and the high sequence identity (80%) 
between MSI2-RRM1 and MSI1-RBD1. Similar to the 
CS-ROSETTA model, the homology model of MSI2-
RRM1 also consists of five β-sheets (β1–β5) at residues 
23–26, 47–52, 64–69, 84–86 and 89–95, and two ɑ 
helices (ɑ1 and ɑ2) at residues 33–42 and 72–82. The 
RMSD between the CS-ROSETTA model and homology 
model is 2.30 Å for 75 equivalent Cα atoms. Both the 
CS-ROSETTA model and the homology model exhibit 
a typical RNP-type fold consisting of four anti-parallel 
β-sheets (β1–β3 and β5) packed against two ɑ helices 
(ɑ1 and ɑ2), and another short β-sheet (β4) forming a 
β-turn with β5. 
RNA binding pocket
The agreement between the overall structures of 
the CS-ROSETTA model and the homology model of 
MSI2-RRM1 encouraged us to use the CS-ROSETTA 
model to identify the RNA binding pocket, and compare 
the binding pocket with that of MSI1-RBD1. Aligning the 
amino acid sequences of MSI2-RRM1 and MSI1-RBD1 
and comparing their secondary structure elements revealed 
a high degree of secondary structure conservation between 
MSI2-RRM1 and MSI1-RBD1 (Figure 5A). Ohyama 
et al. performed an NMR titration of MSI1-RBD1 with 
Numb5 [26]. Based on their results, we highlighted (in 
blue) seventeen residues (F23, I24, G25, G26, S28, W29, 
Q30, T31, M52, S60, R61, G62, G64, F65, K93, V94 
and F96) in MSI1-RBD1 with largest CSPs on a ribbon 
diagram of the MSI1-RBD1 structure (Figure 5B right 
panel). Likewise, Figure 5B (left) shows in red seventeen 
residues (F24, I25, G26, G27, S29, W30, Q31, T32, C50, 
S61, R62, G63, G65, F66, K94, V95 and F97) that were 
significantly affected upon titration of Numb5 in MSI2-
RRM1. In the CS-ROSSETTA model of MSI2-RRM1, 
G21 and K22 are highly flexible, thus, residues G21 and 
K22 in MSI2-RRM1 and their equivalent residues C20 
and K21 in MSI1-RBD1 were not mapped on to the ribbon 
diagram representations. In both proteins, the seventeen 
residues experiencing significant CSPs cluster around 
the central anti-parallel β-sheets and the surrounding 
loops. In MSI1-RBD1, this region is involved directly 
in binding with Numb5 [26]. Therefore, we hypothesize 
that analogous to MSI1-RBD1, the RNA-binding pocket 
of MSI2-RRM1 is also composed of the central anti-
parallel β-sheets and surrounding loops. In the surface 
representations, residues F24, G26, G27, S29, W30, 
Q31, R62, G63, F66, K94, V95 and F97 delineate the 
putative RNA-binding surface of MSI2 (Figure 5C left 
panel). Similarly, in MSI1-RBD1 F23, G25, G26, S28, 
W29, Q30, R61, G62, F65, K93, V94 and F96 lie along 
Figure 2: 1H-15N HSQC spectrum of 15N labeled MSI2-RRM1. The assignments of G21-K111 backbone (1H, 15NH) and W30 
side chain (1Hε, 15Nε) are annotated. 
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the RNA-binding surface where Numb5 binds (Figure 5C 
right panel). Moreover, the CS-ROSETTA model of 
MSI2-RRM1 and the NMR structural model of MSI1-
RBD1 are easily superimposed with an RMSD of 2.29 Å 
for 75 Cα (Figure 6). Taken together, our CSP mapping 
results suggest first, that specific interactions exist between 
MSI2-RRM1 and Numb5, and second, that the perturbed 
residues in MSI2-RRM1 are generally consistent with 
those in MSI1-RBD1, and finally, that MSI2-RRM1 and 
MS1-RBD1 have similar RNA-binding pocket. 
 DISCUSSION
In this study, we characterized the MSI2-RRM1 
protein and Numb RNA interactions using FP, TR-FRET 
and NMR, and revealed the key features of protein- 
RNA binding and the binding pocket. MSI2-RRM1 can 
specifically bind to Numb5 to form a 1:1 complex, and 
the binding process exhibits a slow exchange behavior 
indicative of a high binding affinity. We propose that the 
putative binding pocket of MSI2-RRM1 is composed 
Figure 3: NMR titration of 15N labeled MSI2-RRM1 with Numb5. (A) Overlay of 1H-15N HSQC spectra of MSI2-RRM1 (80 µM) 
in the presence of 0 (red), 0.3(green), 0.5 (orange), 0.7 (cyan), 1.0 (magenta), and 1.3 (blue) molar equivalent of Numb5. Representative 
peaks showing large CSPs are annotated. (B) Weighted CSPs for backbone 1H and 15NH resonances of MSI2-RRM1 when titrated with 
1:1 molar equivalent of Numb5. Weighted CSPs were calculated by the equation: Δδ = [((ΔδH)2 + (ΔδN/5)2)/2]1/2. The value of average 
Δδ plus one standard deviation is 0.1 (indicated by the horizontal dashed line). Δδ values above the horizontal dashed line are significant. 
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of the central anti-parallel β-sheets and the surrounding 
loops in the MSI2-RRM1 CS-ROSETTA model, which 
was supported by the fact that seventeen residues with 
significant CSPs (F24, I25, G26, G27, S29, W30, Q31, 
T32, C50, S61, R62, G63, G65, F66, K94, V95 and F97) 
cluster together and thus probably comprise the binding 
pocket. The putative RNA binding pocket of MSI2-MMR1 
identified in the study contains the canonical RNP motifs 
RNP1 in β3 and RNP2 in β1 [36]. F64 and F66 in RNP1 
and F24 in RNP2 are likely to canonically stack with 
RNA. The putative RNA binding pocket of MSI2-RRM1 
also has unique features that W30 in the loop between β1 
and α1 and F97 in the C-terminal end showed significant 
CSPs, and may involve in non-canonical base stacking 
interactions with RNA. 
MSI2-RRM1 and MSI1-RBD1 have high similarity 
in their RNA-binding characteristics and RNA-binding 
pockets. Both proteins can specifically bind to Numb5 in a 
1:1 stoichiometric manner, and their bound and unbound 
states undergo slow exchange in the NMR chemical 
shift time scale. In both proteins, the residues involved 
in direct interaction with Numb5 are generally consistent, 
moreover, seven residues in MSI2-RRM1 (I25, G27, 
W30, S61, R62, G65 and F97) whose chemical shifts 
were perturbed so significantly (ΔδH > 0.3 ppm) are all 
conserved in MSI1-RBD1, being I24, G26, W29, S60, 
R61, G64 and F96, and indeed they showed pronounced 
CSPs (ΔδH > 0.3 ppm) in MSI1-RBD1. These findings 
indicate both proteins use a similar set of residues to bind 
to Numb5. Their RNA-binding pockets are both formed 
by the central anti-parallel β-sheets and the surrounding 
loops. 
The aromatic residues of MSI1-RBD1 that are 
directly involved in base stacking interactions with Numb5 
are F23, W29, F63, F65, and F96, these five residues are 
conserved in MSI2-RRM1, being F24, W30, F64, F66 
and F97. Specifically, the aromatic rings of F23 and F96 
interact with Ade3, W29 displayed a unique feature that 
its indole ring can stack with Gua1, F65 aromatic ring 
stacks with Gua4, and F63 interacts with Ura2 and Ade3. 
At molar ratio of MSI1-RBD1 to Numb5 of 1, W29 and 
F96 exhibited pronounced CSPs (ΔδH > 0.5 ppm, ΔδN 
> 2.5 ppm), while F23, F63 and F65 experienced lower 
CSPs (ΔδH = ~0.1 ppm, ΔδN = ~0.5 ppm). Our CSPs 
Figure 4: MSI2-RRM1 structure prediction. (A) Backbone atoms superposition of residues 23–100 for the 10 lowest energy 
CS-ROSETTA structures of MSI2-RRM1. (B) Ribbon diagram representation of the lowest energy CS-ROSETTA structure of MSI2-
RRM1. Unstructured regions including residues –3–22 and 101–111 are not shown. The five β-sheets are labeled β1–β5 and the two 
ɑ-helices are labeled ɑ1 and ɑ2. (C) Ribbon diagram representation of the homology model of MSI2-RRM1 (residues 23–100) generated 
by SWISS-MODEL. 
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analysis results revealed that titrating Numb5 into MSI2-
RRM1 induced significant CSPs for residues W30 and 
F97 (ΔδH > 0.5 ppm, ΔδN > 2.5 ppm), and F24, F64 and 
F66 exhibited lower CSPs in the range of 0.08–0.17 ppm. 
Therefore, the CSPs events observed here for F24, W30, 
F64, F66 and F97 in MSI2-RRM1, together with the high 
similarity between the overall foldings of MSI2-RRM1 and 
MSI1-RBD1, provide evidence that similar tryptophan-
guanine, phenylalanine-adenine, phenylalanine-uracil 
and phenylalanine-guanine base stacking interactions are 
present in MSI2-RRM1. 
Taken together, the existence of similarities in the 
CSPs of MSI2-RRM1 and MSI1-RBD1 due to RNA 
binding suggests the possibility of identifying novel 
small molecule inhibitors that are MSI2-specific as well 
as others that can function as MSI1/MSI2 dual inhibitors. 
Such inhibitors could potentially disrupt these unique 
MSI2-RNA aromatic amino acids mediated base stacking 
interactions or MSI-RNA interactions, thus leading to 
inhibition of MSI1/MSI2-mediated biological functions 
and compromising, among others, the viability of cancer 
cells that depend on MSI1/MSI2. Combined with our 
Figure 5: Sequence alignment and CSPs mapping of MSI2-RRM1 and MSI1-RBD1. (A) Sequence alignment of MSI2-
RRM1 (residues 21–111) and MSI1-RBD1 (residues 20–103). Identical residues are indicated by asterisks, conversed residues by colons 
and semi-conserved residues by periods. The secondary structure elements in MSI2-RRM1 and MSI1-RBD1 are shown as arrows (β-sheets) 
and cylinders (α-helices). In MSI2-RRM1, residues with CSPs higher than 0.1 ppm are colored red. In MSI1-RBD1, residues that show 
pronounced CSPs are colored blue. (B) Mapping of CSPs data on to the ribbon diagram representations of the CS-ROSETTA model of 
MSI2-RRM1 and the NMR structural model of MSI1-RBD1 (PDB 2RS2). (C) Mapping of CSPs data on to the surface representations of 
the CS-ROSETTA model of MSI2-RRM1 and the NMR structural model of MSI1-RBD1 (PDB 2RS2). Numb5 is colored cyan. 
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other efforts in discovering chemical probes, e.g. fragment 
based drug screening, obtaining the solution structure 
of MSI2-RRM1 will help the development of MSI1/2 
inhibitors with structure-based rational design (Docking 
with NMR data) to discover compounds that fit the long 
narrow RNA-binding pocket of MSI2. 
MATERIALS AND METHODS
Binding assays
Numb mRNA contains the Musashi recognition 
motif r(UAG), and is a binding target shared by both 
MSI1 and MSI2. In order to dissect the similarities 
and differences between MSI1 and MSI2 in the RNA-
binding pocket, we used the same 15 nt Numb RNA 
(5ʹUAGGUAGUAGUUUUA) for our binding assays 
and the same 5nt Numb RNA (GUAGU) for the NMR 
studies as our previous study [33]. FP assay was carried 
out using a FITC (fluorescein isothiocyanate) labeled 
Numb RNA (NumbFITC: 5ʹUAGGUAGUAGUUUUA-
FITC) according to our previous publication [33]. 
TR-FRET assay was carried out using Streptavidin-d2 
beads (610SADLA, Cisbio, Bedford, MA) and MAb Anti-
6HIS Tb cryptate Gold beads (61HI2TLA, Cisbio) in HTRF 
96 well low volume plate (66PL96005, Cisbio) following 
the protocol recommended by the manufacturer. Fluorescent 
measurements were taken at room temperature using a 
BioTek Synergy H4 plate reader (Biotek, Winooski, VT). 
Protein expression and purification
The MSI2-RRM1 domain was sub-cloned into the 
pTGSG vector using the Ligation Independent Cloning 
method as described [37]. The non-labelled MSI2-RRM1 
protein was expressed in E. coli BL21(DE3) pRARE 
and purified as previously described [33], and was kept 
in the buffer of 50 mM Tris-HCl, pH 8.0, 500 mM NaCl 
till use. The isotopically labelled protein was expressed 
in M9 medium using C13 glucose and N15 Ammonium 
Chloride as sole carbon and nitrogen source, respectively. 
The isotope uniformly labeled protein was isolated and 
purified using the same method as that of the unlabeled 
protein and then further purified through a SuperdexTM 
75 10/300 GL column equilibrated with 20 mM MES, pH 
6.0, 150 mM NaCl. The protein was then concentrated 
and 5% D2O was added for NMR spectroscopy; Protein 
purity was assessed on coommassie stained acrylamide 
gel and protein concentrations were determined using the 
Bradford assay (Bio-Rad, Hercules, CA). 
NMR spectroscopy
All NMR experiments were performed at 298 K 
on a Bruker AVANCE 800 MHz spectrometer equipped 
with a triple resonance cryoprobe and a Bruker AVANCE 
600 MHz spectrometer equipped with a triple resonance 
room temperature probe. The NMR buffer was 
20 mM MES (pH 6.0), 150 mM NaCl and 5% D2O for 
spectrometer lock. NMR data were processed using the 
NMRPipe program [38] and visualized and analyzed using 
CCPN Analysis [39] and NMRViewJ [40]. 
Triple resonance NMR data were collected using 
13C and 15N labeled MSI2-RRM1 samples in the range 
of 0.4–0.8 mM at volumes of 0.5–0.6 mL in standard 
5 mm NMR tubes. Backbone resonance assignments 
were made by analyzing HNCA, HNCACB, HN(CO)CA, 
CBCACONH, HNCO and HN(CA)CO spectra [41–44]. 
Figure 6: Overlay of the CS-ROSETTA model of MSI2-RRM1 (red) and the NMR structural model of MSI1-RBD1 
(blue).
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15N-etited NOESY-HSQC (120 ms mixing time) was 
collected using a sample containing 0.4 mM 15N labeled 
MSI2-RRM1 and 0.4 mM unlabeled Numb5.
1H-15N HSQC titration experiment was performed 
using 80 µM 15N-labeled MSI2-RRM1. Unlabeled 
r(GUAGU) (Numb5) stock solution was titrated into 
the MSI2-RRM1 sample to protein to ligand molar 
ratio of 1:0, 1:0.3,1:0.5, 1:0.7, 1:1 and 1:1.3. A 1H-15N 
HSQC spectrum was recorded for each titration point. 
Combined CSPs (Δδ) were calculated using the equation 
Δδ = [((ΔδH)2 + (ΔδN/5)2)/2]1/2. Where ΔδH and ΔδN are 
chemical shift changes of 1H and 15NH, respectively. 
CS-ROSETTA modeling and homology modeling
The CS-ROSETTA structures of MSI2-RRM1 
(residues M23-R100) were calculated using the CS-
ROSETTA server (https://csrosetta.bmrb.wisc.edu/
csrosetta), utilizing the protein backbone 1H, 15NH, 
13Cα and 13C’ chemical shifts of MSI2-RRM1 deposited 
in BMRB under accession code 27111. Twenty-four 
homologous sequences, including MSI1-RBD1 sequences 
(PDB IDs 1UAW and 2RS2), have PSI-BLAST e-scores 
< 0.05 and were excluded before the fragment search 
procedure. The homology model of MSI2-RRM1 was 
generated using the SWISS-MODEL server [45]. Residues 
G21 to K111 was aligned with the MSI1-RBD1 template 
(PDB ID 2RS2). The query and template sequence identity 
was 78%. The resulting model had a GMQE score of 0.65 
and QMEAN score of –0.69. 
Abbreviations
Musashi (MSI); RNA-recognition Motifs (RRMs); 
RNA-binding Domains (RBDs); Nuclear Magnetic 
Resonance (NMR); RNA-binding proteins (RBPs); 
heterogeneous nuclear ribonucleoproteins (hnRNPs); 
ribonucleoprotien (RNP); florescence polarization (FP); 
time resolved Fluorescence Resonance Energy Transfer 
(TR-FRET); Chemical shift perturbations (CSPs); protein 
data bank (PDB); root-mean-square-deviation (RMSD).
ACKNOWLEDGMENTS
We thank Hongyang Yao at BMRB for generating 
the CS-ROSETTA structures of MSI2 RRM1.
CONFLICTS OF INTEREST
The authors declare no competing interest.
FUNDING 
This study was supported in part by National 
Institutes of Health grants R01 CA178831 and CA191785, 
NIH COBRE-PSF at KU (P30 GM110761) Pilot Project, 
Department of Defense Breast Cancer Research Program 
Breakthrough Level II grant BC151845, and Kansas 
Bioscience Authority Rising Star Award (to LX). 
REFERENCES
 1. Sutherland JM, McLaughlin EA, Hime GR, Siddall NA. 
The musashi family of RNA binding proteins: master 
regulators of multiple stem cell populations. Adv Exp Med 
Biol. 2013; 786:233–245.
 2. Sakakibara S, Nakamura Y, Yoshida T, Shibata S, Koike M, 
Takano H, Ueda S, Uchiyama Y, Noda T, Okano H. RNA-
binding protein Musashi family: roles for CNS stem cells 
and a subpopulation of ependymal cells revealed by targeted 
disruption and antisense ablation. Proc Natl Acad Sci U S A. 
2002; 99:15194–15199.
 3. Sakakibara S, Nakamura Y, Satoh H, Okano H. Rna-binding 
protein Musashi2: developmentally regulated expression in 
neural precursor cells and subpopulations of neurons in 
mammalian CNS. J Neurosci. 2001; 21:8091–8107.
 4. Gunter KM, McLaughlin EA. Translational control in germ 
cell development: A role for the RNA-binding proteins 
Musashi-1 and Musashi-2. IUBMB life. 2011; 63:678–685.
 5. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, 
Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, 
Einhorn W, Lane SW, et al. Musashi-2 regulates normal 
hematopoiesis and promotes aggressive myeloid leukemia. 
Nat Med. 2010; 16:903–908.
 6. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, 
Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, 
Kim SH, et al. Regulation of myeloid leukaemia by the cell-
fate determinant Musashi. Nature. 2010; 466:765–768.
 7. Griner LN, Reuther GW. Aggressive myeloid leukemia 
formation is directed by the Musashi 2/Numb pathway. 
Cancer Biol Ther. 2010; 10:979–982.
 8. Aly RM, Ghazy HF. Prognostic significance of MSI2 
predicts unfavorable outcome in adult B-acute lymphoblastic 
leukemia. Int J Lab Hematol. 2015; 37:272–278.
 9. Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, 
Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, 
Hemmati P, van Lessen A, Amini L, et al. Up-regulated 
MSI2 is associated with more aggressive chronic myeloid 
leukemia. Leuk Lymphoma. 2015; 56:2105–2113.
10. Thol F, Winschel C, Sonntag AK, Damm F, Wagner K, 
Chaturvedi A, Gohring G, Schlegelberger B, Lubbert M, 
Fiedler W, Kirchner H, Krauter J, Ganser A, Heuser M. 
Prognostic significance of expression levels of stem cell 
regulators MSI2 and NUMB in acute myeloid leukemia. 
Ann Hematol. 2013; 92:315–323.
11. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 
protein expression predicts unfavorable outcome in acute 
myeloid leukemia. Blood. 2011; 118:2857–2867.
12. Wang S, Li N, Yousefi M, Nakauka-Ddamba A, Li F, Parada 
K, Rao S, Minuesa G, Katz Y, Gregory BD, Kharas MG, Yu 
Oncotarget106596www.impactjournals.com/oncotarget
Z, Lengner CJ. Transformation of the intestinal epithelium 
by the MSI2 RNA-binding protein. Nat Commun. 2015; 
6:6517. 
13. Li N, Yousefi M, Nakauka-Ddamba A, Li F, Vandivier L, 
Parada K, Woo DH, Wang S, Naqvi AS, Rao S, Tobias J, 
Cedeno RJ, Minuesa G, et al. The Msi Family of RNA-
Binding Proteins Function Redundantly as Intestinal 
Oncoproteins. Cell Reports. 2015; 13:2440–2455.
14. Zong Z, Zhou T, Rao L, Jiang Z, Li Y, Hou Z, Yang B, 
Han F, Chen S. Musashi2 as a novel predictive biomarker 
for liver metastasis and poor prognosis in colorectal cancer. 
Cancer Med. 2016; 5:623–630.
15. Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, 
Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, 
Cai KQ, Yaghmour KM, Baker KA, et al. Musashi-2 
(MSI2) supports TGF-beta signaling and inhibits claudins 
to promote non-small cell lung cancer (NSCLC) metastasis. 
Proc Natl Acad Sci U S A. 2016; 113:6955–6960.
16. Sheng W, Dong M, Chen C, Wang Z, Li Y, Wang K, Li Y, 
Zhou J. Cooperation of Musashi-2, Numb, MDM2, and 
P53 in drug resistance and malignant biology of pancreatic 
cancer. FASEB J. 2017; 31:2429–38.
17. Guo K, Cui J, Quan M, Xie D, Jia Z, Wei D, Wang L, Gao Y, 
Ma Q, Xie K. The Novel KLF4/MSI2 Signaling Pathway 
Regulates Growth and Metastasis of Pancreatic Cancer. Clin 
Cancer Res. 2017; 23:687–696.
18. Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, 
Koechlein CS, Zimdahl B, Yano M, Kopp JL, Kritzik M, 
Sicklick JK, Sander M, et al. Image-based detection and 
targeting of therapy resistance in pancreatic adenocarcinoma. 
Nature. 2016; 534:407–411.
19. Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, 
Rizzino A. The SOX2-interactome in brain cancer cells 
identifies the requirement of MSI2 and USP9X for the 
growth of brain tumor cells. PLoS One. 2013; 8:e62857.
20. Kudinov AE, Karanicolas J, Golemis EA, Boumber Y. 
Musashi RNA-binding proteins as cancer drivers and novel 
therapeutic targets. Clin Cancer Res. 2017; 23:2143–53.
21. Fox RG, Park FD, Koechlein CS, Kritzik M, Reya T. 
Musashi signaling in stem cells and cancer. Annu Rev Cell 
Dev Biol. 2015; 31:249–267.
22. Kharas MG, Lengner CJ. Stem Cells, Cancer, and MUSASHI 
in Blood and Guts. Trends Cancer. 2017; 3:347–356.
23. Lee J, An S, Choi YM, Lee J, Ahn KJ, Lee JH, Kim TJ, 
An IS, Bae S. Musashi-2 is a novel regulator of paclitaxel 
sensitivity in ovarian cancer cells. Int J Oncol. 2016; 
49:1945–1952.
24. Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun L, Jiang S, 
Wu J, Yu K, Zhang S. Musashi-2 Silencing Exerts Potent 
Activity against Acute Myeloid Leukemia and Enhances 
Chemosensitivity to Daunorubicin. PLoS One. 2015; 
10:e0136484.
25. Zearfoss NR, Deveau LM, Clingman CC, Schmidt 
E, Johnson ES, Massi F, Ryder SP. A conserved 
three-nucleotide core motif defines Musashi RNA binding 
specificity. J Biol Chem. 2014; 289:35530–35541.
26. Ohyama T, Nagata T, Tsuda K, Kobayashi N, Imai T, Okano H, 
Yamazaki T, Katahira M. Structure of Musashi1 in a 
complex with target RNA: the role of aromatic stacking 
interactions. Nucleic Acids Res. 2012; 40:3218–3231.
27. Imai T, Tokunaga A, Yoshida T, Hashimoto M, Mikoshiba K, 
Weinmaster G, Nakafuku M, Okano H. The neural 
RNA-binding protein Musashi1 translationally regulates 
mammalian numb gene expression by interacting with its 
mRNA. Mol Cell Biol. 2001; 21:3888–3900.
28. Jadhav S, Ajay AK, Trivedi P, Seematti J, Pellegrini K, 
Craciun F, Vaidya VS. RNA-binding Protein Musashi 
Homologue 1 Regulates Kidney Fibrosis by Translational 
Inhibition of p21 and Numb mRNA. J Biol Chem. 2016; 
291:14085–14094.
29. Nagata T, Kanno R, Kurihara Y, Uesugi S, Imai T, 
Sakakibara S, Okano H, Katahira M. Structure, backbone 
dynamics and interactions with RNA of the C-terminal 
RNA-binding domain of a mouse neural RNA-binding 
protein, Musashi1. J Mol Biol. 1999; 287:315–330.
30. Miyanoiri Y, Kobayashi H, Imai T, Watanabe M, Nagata T, 
Uesugi S, Okano H, Katahira M. Origin of Higher Affinity 
to RNA of the N-terminal RNA-binding Domain than That 
of the C-terminal One of a Mouse Neural Protein, Musashi1, 
as Revealed by Comparison of Their Structures, Modes of 
Interaction, Surface Electrostatic Potentials, and Backbone 
Dynamics. J Biol Chem. 2003; 278:41309–41315.
31. Clingman CC, Deveau LM, Hay SA, Genga RM, 
Shandilya SM, Massi F, Ryder SP. Allosteric inhibition 
of a stem cell RNA-binding protein by an intermediary 
metabolite. eLife. 2014; 3:3.
32. Minuesa G, Antczak C, Shum D, Radu C, Bhinder B, Li Y, 
Djaballah H, Kharas MG. A 1536-well fluorescence 
polarization assay to screen for modulators of the 
MUSASHI family of RNA-binding proteins. Comb Chem 
High Throughput Screen. 2014; 17:596–609.
33. Lan L, Appelman C, Smith AR, Yu J, Larsen S, Marquez RT, 
Liu H, Wu X, Gao P, Roy A, Anbanandam A, Gowthaman R, 
Karanicolas J, et al. Natural product (–)-gossypol inhibits 
colon cancer cell growth by targeting RNA-binding protein 
Musashi-1. Mol Oncol. 2015; 9:1406–20. 
34. Shen Y, Lange O, Delaglio F, Rossi P, Aramini JM, Liu G, 
Eletsky A, Wu Y, Singarapu KK, Lemak A, Ignatchenko A, 
Arrowsmith CH, Szyperski T, et al. Consistent blind protein 
structure generation from NMR chemical shift data. Proc 
Natl Acad Sci U S A. 2008; 105:4685–4690.
35. Shen Y, Vernon R, Baker D, Bax A. De novo protein 
structure generation from incomplete chemical shift 
assignments. J Biomol NMR. 2009; 43:63–78.
36. Clery A, Blatter M, Allain FH. RNA recognition motifs: 
boring? Not quite. Curr Opin Struct Biol. 2008; 18:290–298.
37. Qin H, Hu J, Hua Y, Challa SV, Cross TA, Gao FP. 
Construction of a series of vectors for high throughput 
Oncotarget106597www.impactjournals.com/oncotarget
cloning and expression screening of membrane proteins from 
Mycobacterium tuberculosis. BMC Biotechnol. 2008; 8:51.
38. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 
NMRPipe: a multidimensional spectral processing system 
based on UNIX pipes. J Biomol NMR. 1995; 6:277–293.
39. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, 
Llinas M, Ulrich EL, Markley JL, Ionides J, Laue ED. The 
CCPN data model for NMR spectroscopy: development of 
a software pipeline. Proteins. 2005; 59:687–696.
40. Johnson BA, Blevins RA. NMR View: A computer program 
for the visualization and analysis of NMR data. J Biomol 
NMR. 1994; 4:603–614.
41. Grzesiek S, Bax A. An Efficient Experiment for Sequential 
Backbone Assignment of Medium-Sized Isotopically 
Enriched Proteins. J Magn Reson. 1992; 99:201–207.
42. Grzesiek S, Bax A. Improved 3d Triple-Resonance Nmr 
Techniques Applied to a 31-Kda Protein. J Magn Reson. 
1992; 96:432–440.
43. Muhandiram DR, Kay LE. Gradient-Enhanced Triple-
Resonance 3-Dimensional Nmr Experiments with Improved 
Sensitivity. J Magn Reson B. 1994; 103:203–216.
44. Kay LE, Xu GY, Yamazaki T. Enhanced-Sensitivity Triple-
Resonance Spectroscopy with Minimal H2o Saturation. 
J Magn Reson A. 1994; 109:129–133.
45. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, 
Schmidt T, Kiefer F, Gallo Cassarino T, Bertoni M, Bordoli L, 
Schwede T. SWISS-MODEL: modelling protein tertiary 
and quaternary structure using evolutionary information. 
Nucleic Acids Res. 2014; 42:W252–258.
